Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening
- PMID: 33544908
- DOI: 10.1002/hep.31736
Gene Signatures Reduce the Stress of Preclinical Drug Hepatotoxicity Screening
References
-
- Monroe JJ, Tanis KQ, Podtelezhnikov AA, Nguyen T, Machotka SV, Lynch D, et al. Application of a rat liver drug bioactivation transcriptional response assay early in drug development that informs chemically reactive metabolite formation and potential for drug-induced liver injury. Toxicol Sci 2020;177:281-299.
-
- Podtelezhnikov AA, Monroe JJ, Aslamkhan AG, Pearson K, Qin C, Tamburino AM, et al. Quantitative transcriptional biomarkers of xenobiotic receptor activation in rat liver for the early assessment of drug safety liabilities. Toxicol Sci 2020;175:98-112.
-
- Kang W, Podtelezhnikov AA, Tanis KQ, Pacchione S, Su M, Bleicher KB, et al. Development and application of a transcriptomic signature of bioactivation in an advanced in vitro liver model to reduce drug-induced liver injury risk early in the pharmaceutical pipeline. Toxicol Sci 2020;177:121-139.
-
- Copple IM, den Hollander W, Callegaro G, Mutter FE, Maggs JL, Schofield AL, et al. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: Implications for prediction of drug-induced liver injury. Arch Toxicol 2019;93:385-399.
-
- Jang KJ, Otieno MA, Ronxhi J, Lim HK, Ewart L, Kodella KR, et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci Transl Med 2019;11:eaax5516.
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
